NSF International has announced it will provide independent testing, verification, auditing, and certification services to consumer products containing hemp and hemp-derived cannabidiol (CBD), including food, dietary supplements, and personal care products.
As the Centers for Disease Control continues its investigation into vaping-related illnesses, and several states consider banning the sale of flavored vape products, the Natural Products Association is warning Congress that this public health crisis may inevitably extend to cannabidiol (CBD) products.
According to a report recently published by the American Herbal Products Association dietary supplement recalls are relatively infrequent.
AIDP Inc. has achieved pre-market approval for novel prebiotic claims after collaborating with the full-service contract research organization Nutrasource Pharmaceutical and Nutraceutical Services.
NuLiv Science has announced that its InnoSlim ingredient is self-affirmed GRAS after the firm engaged AIBMR Life Sciences, Inc. to convene a panel of experts qualified by training and experience to evaluate the safety of food ingredients.
Industry associations, testing labs, suppliers, and finished product manufacturers are exercising due diligence, each in their own way, to self-regulate and promote responsible behavior, claims, and best practices in an immature hemp and CBD market.
USDA’s Risk Management Agency announced that industrial hemp growers will be able to obtain insurance coverage under the Whole-Farm Revenue Protection program for crop year 2020, if their hemp is grown for fiber, flower, and seeds.
Arla Foods Ingredients received a “no objection” GRAS (generally recognized as safe) notice from FDA for the use of alpha-lactalbumin in infant formula.
Where do hemp and cannabinoid companies fit in the manufacturing standards regimen? This has become the question in the absence of clear FDA guidance and regulations for manufacturing.
Prenexus Health has received a “no questions” letter from FDA following its GRAS (generally recognized as safe) notification for the use of its xylooligosaccharide (XOS) prebiotic, at levels up to 2.4 grams per day, in a variety of foods.
Four Sabinsa manufacturing sites in Kunigal, Dobaspet, Hyderabad, and Nelamangala, India have received Foundation Food Safety System Certification 22000 (FSSC 22000) certification.
What does research say about CBD’s potential role in sports recovery, and how do sports regulatory bodies view its use?
ExcelVite has announced that it has obtained certification from the Malaysian Sustainable Palm Oil Supply Chain Certification Standard (MSPO SCCS) after an extensive audit by the Standard and Industrial Research Institute of Malaysia.
Deerland Probiotics and Enzymes has announced that it has received a GRAS (generally recognized as safe) no-objection letter for FDA for its Bacillus subtilis DE111 branded probiotic.
Chemi Nutra warns that synthetic Alpha-Glyceryl Phosphoryl Choline is making its way into the market by posing as the company’s branded ingredient.
ChromaDex is one step closer to regulatory approval in the European Union with this positive opinion from the European Food Safety Authority.
Prior to FDA's amended color additive regulation, soy leghemoglobin, used in the Impossible Burger for meat-like taste, texture, and aroma was only approved in products sold to consumers in cooked form, meaning that Impossible Burger was only available in participating food service locations.
The authors write: “It seems that foods and beverages containing CBD are likely to remain high-risk, while dietary supplements would appear to be a slightly lower-risk option for manufacturers or distributors of CBD-containing products.”
Natural Remedies' branded turmeric extract, Turmacin, is now self-affirmed GRAS (generally recognized as safe).
Former FDA commissioner Scott Gottlieb, MD recently wrote an opinion piece in the Washington Post about how the agency should handle cannabidiol (CBD) in food and dietary supplements.
Amarin Pharma has filed a petition for certiorari asking the Supreme Court to review a decision made by the U.S. Court of Appeals for the Federal Circuit to uphold a 2017 decision of the International Trade Commission (ITC) not to investigate Amarin’s complaints against manufacturers of omega-3 EPA concentrates.
The meeting convened federal agencies USDA, FDA, and EPA as well as the testimony of industry stakeholders providing important perspectives when it comes to farming and testing of hemp crops and extracts.
As FDA considers a potential regulatory pathway for hemp-derived CBD products, the agency continues to take action against firms making unsubstantiated claims.
Amarin Pharma’s recent comments advising FDA not to allow synthetic omega-3 supplements to be dietary supplements is just one more case in which synthetic supplement ingredients are under fire.
A coalition of 37 state attorneys general are urging FDA to cooperate with the states in developing regulation of CBD and other cannabis-derived products.
In public comments submitted to FDA on July 15, 2019, the American Herbal Products Association made a number of suggestions to the agency, which has been in dialogue with the industry to modernize regulation of dietary supplements.
Many groups submitted public comments to FDA this week, following FDA’s recent May 31 open hearing on the issue of CBD regulation and call for public comment.
FDA has not exhausted its current arsenal of tools, such as import alerts, to enforce new dietary ingredients notifications, says NPA.
In comments submitted to FDA, Amarin Pharma, maker of the omega-3 drug Vascepa, stated its intentions to file a citizen petition to FDA asserting that ethyl ester omega-3s are not legally allowed to be marketed as dietary supplements.
The Council for Responsible Nutrition (CRN; Washington, DC) this week submitted public comments to FDA addressing the agency’s plans to evaluate and potentially update regulations for dietary supplements.
